MARKET

VBLT

VBLT

VASCULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.280
-0.020
-1.54%
Opening 15:13 08/10 EDT
OPEN
1.300
PREV CLOSE
1.300
HIGH
1.330
LOW
1.280
VOLUME
85.24K
TURNOVER
--
52 WEEK HIGH
1.640
52 WEEK LOW
0.9000
MARKET CAP
61.31M
P/E (TTM)
-2.2300
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VBLT stock price target is 3.850 with a high estimate of 5.00 and a low estimate of 2.500.

EPS

VBLT News

More
Earnings Preview: Vascular Biogenics (VBLT) Q2 Earnings Expected to Decline
Zacks · 4d ago
VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13
GlobeNewswire · 08/03 13:00
MORNING BID-Fog, stall ... rally
Reuters · 07/15 09:16
Growth Investors: Industry Analysts Just Upgraded Their Vascular Biogenics Ltd. (NASDAQ:VBLT) Revenue Forecasts By 24%
Simply Wall St. · 06/25 14:02
VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
GlobeNewswire · 06/22 13:00
NIO, SPCE among premarket gainers
Seeking Alpha - Article · 06/22 12:21
VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity And Potential Survival Benefit For Solid Tumors In Late Breaking Research Session Of AACR Virtual Annual Meeting
Benzinga · 06/22 12:02
VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress
GlobeNewswire · 06/04 12:00

Industry

Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
+0.12%

Hot Stocks

Symbol
Price
%Change

About VBLT

Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.
More

Webull offers kinds of Vascular Biogenics Ltd stock information, including NASDAQ:VBLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VBLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VBLT stock methods without spending real money on the virtual paper trading platform.